Search

Your search keyword '"Laplaud, David"' showing total 636 results

Search Constraints

Start Over You searched for: Author "Laplaud, David" Remove constraint Author: "Laplaud, David"
636 results on '"Laplaud, David"'

Search Results

1. Investigating the metabolite signature of an altered oral microbiota as a discriminant factor for multiple sclerosis: a pilot study

2. Frequency and clinical relevance of MOG-antibodies in CSF in pediatric patients with MOG antibody-associated diseases

4. A meta‐analysis comparing first‐line immunosuppressants in neuromyelitis optica

8. Frequency and clinical relevance of MOG-antibodies in CSF in pediatric patients with MOG antibody-associated diseases

11. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

12. Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal

14. Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference

16. Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGADin Adults: The MOGADOR2 Study.

21. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

22. Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study

25. Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations

26. Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis

27. A French cohort for assessing COVID-19 vaccine responses in specific populations

30. COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022

31. Comparison of 2 Methods for Estimating Multiple Sclerosis–Related Mortality

32. 2367. Six-month Humoral Response Following Two Or Three Doses Of Covid-19 Vaccines As Primary Vaccination Followed Or Not By a Booster Dose In Specific Populations – ANRS0001S COV-POPART Cohort Study

33. Cytotoxic CD8⁺ T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons

34. Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data

35. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

36. The biological sample collection of the OFSEP French MS registry: An essential tool dedicated to researchers

37. Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data

38. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

39. Effect of general anaesthesia on functional outcome in patients with anterior circulation ischaemic stroke having endovascular thrombectomy versus standard care: a meta-analysis of individual patient data

40. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy

41. Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis

44. CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome

45. Gut bacteria Akkermansia elicit a specific IgG response in CSF of patients with MS

47. Microglial control of astrocytes in response to microbial metabolites

49. The radiologically isolated syndrome: revised diagnostic criteria

50. Aglycosylated extracellular loop of inwardly rectifying potassium channel 4.1 (KCNJ10) provides a target for autoimmune neuroinflammation

Catalog

Books, media, physical & digital resources